<DOC>
	<DOCNO>NCT00000899</DOCNO>
	<brief_summary>The purpose study determine safety anti-HIV drug combine low-dose chemotherapy ( consist cyclophosphamide [ CTX ] ) HIV-positive patient . This study examine whether combination therapy reduce number HIV-infected cell hidden lymph node blood . Current anti-HIV drug treatment greatly reduce level HIV human body . However , HIV hide certain immune cell escape drug ' effect . Chemotherapy use CTX destroy immune cell . When used standard anti-HIV drug treatment , CTX may able speed elimination HIV-infected cell .</brief_summary>
	<brief_title>A Study Effect Chemotherapy Combined With Anti-HIV Drugs HIV-Positive Patients</brief_title>
	<detailed_description>HAART potent suppressor plasma lymph node HIV RNA . However , study suggest HAART significantly diminish reservoir chronically HIV-infected cell . Strategies design eradicate HIV infection seek actively target reservoir . CTX administration show eliminate large number lymphoid tissue T cell macrophage , appear actively target chronically HIV-infected cell . As lymphoid organ repopulated follow initial depletion CTX , HAART may protect repopulating cell become HIV-infected , result net additional removal HIV-infected lymphoid reservoir . In Step 1 2-step protocol , patient receive HAART regimen nelfinavir ( NFV ) plus stavudine ( d4T ) plus lamivudine ( 3TC ) . Patients achieve acceptable virologic response , define 2 consecutive HIV RNA determination 500 copies/ml least 2 week apart Weeks 4 16 Step 1 [ AS PER AMENDMENT 10/30/98 : define 2 consecutive plasma HIV RNA determination 50 copies/ml Roche Ultrasensitive assay within 4-week period Weeks 4 24 ] , randomize Arm A B Step 2 . In Arm A , patient receive NFV plus d4T plus 3TC . In Arm B , patient receive NFV plus d4T plus 3TC plus 3 escalating dos CTX 6-week interval . Patients arm follow least 52 week follow randomization Step 2 . During time , patient undergo blood test lymph node biopsy measure HIV DNA RNA level characterize T cell population . Additionally , patient undergo chest CT thymus randomization Step 2 Week 52 Step 2 . Cerebrospinal fluid may obtain Week 52 determine amount HIV RNA DNA present . [ AS PER AMENDMENT 10/30/98 : G-CSF give first dose CTX , discretion investigator , second third dos , 14 day , absolute neutrophil count 10,000 cells/mm3 . Also , CTX dose may modify base pharmacokinetic study result . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 count 300 cells/mm3 within 30 day study entry . Have HIV viral load 10,000 200,000 copies/ml . Are age 18 50 . Agree practice abstinence use barrier method birth control study ( condom ) . Exclusion Criteria You may eligible study : Have cancer require chemotherapy radiotherapy certain nervous system disease . Are sensitive E. coliderived protein . Have active AIDSdefining illness . Require certain medication . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Lymph Nodes</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>DNA , Viral</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
</DOC>